Elisabetta Bianchini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabetta Bianchini has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Faita
Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy
18 shared publications Vincenzo Gemignani
National Research Council (CNR), Institute of Clinical Physiology, Pisa, Italy; Quipu srl, Pisa, Italy
17 shared publications- Lorenzo Ghiadoni
Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy
14 shared publications - Rosa Maria Bruno
Paris Cardiovascular Research Center (PARCC), Université Paris Cité, Inserm , Paris
14 shared publications Francesco Faita
National Research Council (CNR), Institute of Clinical Physiology, Pisa, Italy
8 shared publicationsChiara Giannarelli
Department of Clinical and Experimental Medicine, University of Pisa
7 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Elsevier in Heart, Lung and Circulation
Sensor-Based Force-Frequency Relation Assessment in Personalised Cardiovascular Care: An Overview
- 14 November 2026
- Published by Elsevier in Heart, Lung and Circulation
Open AccessSensor-Based Force-Frequency Relation Assessment in Personalised Cardiovascular Care: An Overview
- Open Access
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 23 (10) , 1171-1186
Overcoming the opaque side of AI in healthcare: a lifecycle-based approach
1. Artificial intelligence/machine learning (AI/ML)-enabled medical devices are increasingly used in the healthcare domain. These technologies can potentially facilitate earlier disease detection a...
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 23 (10) , 1171-1186
Open AccessOvercoming the opaque side of AI in healthcare: a lifecycle-based approach
1. Artificial intelligence/machine learning (AI/ML)-enabled medical devices are increasingly used in the healthcare domain. These technologies can potentially facilitate earlier disease detection a...
- Open Access
- 11 June 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 285, 109516
Tonometer- and ultrasound-based pulse wave analysis – a comparative study
- 11 June 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 285, 109516
Open AccessTonometer- and ultrasound-based pulse wave analysis – a comparative study
- Open Access
- 27 May 2026
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 52 (8) , 1753-1762
Integrating Structural and Functional Ultrasound Carotid Assessment in a Single Software Platform: Development and Feasibility Evaluation
- 27 May 2026
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 52 (8) , 1753-1762
Open AccessIntegrating Structural and Functional Ultrasound Carotid Assessment in a Single Software Platform: Development and Feasibility Evaluation
- Open Access
- 21 May 2026
- Published by Elsevier in Health Policy and Technology
- Vol. 15 (7)
A regulation-based project lifecycle for innovative medical devices: Delphi consensus from an Italian expert panel
- 21 May 2026
- Published by Elsevier in Health Policy and Technology
- Vol. 15 (7)
Open AccessA regulation-based project lifecycle for innovative medical devices: Delphi consensus from an Italian expert panel
- Open Access
- 1 December 2024
- Published by IOP Publishing in Physiological Measurement
- Vol. 45 (12) , 121001
Developing technologies to assess vascular ageing: a roadmap from VascAgeNet
Vascular ageing (vascular ageing) is the deterioration of arterial structure and function which occurs naturally with age, and which can be accelerated with disease. Measurements of vascular ageing are emerging as markers of cardiovascular risk, with potential applications in disease diagnosis and prognosis, and for guiding treatments. However, vascular ageing is not yet routinely assessed in clinical practice. A key step towards this is the development of technologies to assess vascular ageing. In this Roadmap, experts discuss several aspects of this process, including: measurement technologies; the development pipeline; clinical applications; and future research directions. The Roadmap summarises the state of the art, outlines the major challenges to overcome, and identifies potential future research directions to address these challenges.
- 1 December 2024
- Published by IOP Publishing in Physiological Measurement
- Vol. 45 (12) , 121001
Open AccessDeveloping technologies to assess vascular ageing: a roadmap from VascAgeNet
Vascular ageing (vascular ageing) is the deterioration of arterial structure and function which occurs naturally with age, and which can be accelerated with disease. Measurements of vascular ageing are emerging as markers of cardiovascular risk, with potential applications in disease diagnosis and prognosis, and for guiding treatments. However, vascular ageing is not yet routinely assessed in clinical practice. A key step towards this is the development of technologies to assess vascular ageing. In this Roadmap, experts discuss several aspects of this process, including: measurement technologies; the development pipeline; clinical applications; and future research directions. The Roadmap summarises the state of the art, outlines the major challenges to overcome, and identifies potential future research directions to address these challenges.
- Top Cited PapersOpen Access
- 1 January 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (1) , 183-192
2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices
BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.
- 1 January 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (1) , 183-192
Top Cited PapersOpen Access2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices
BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e027414
Magnetic Resonance Imaging and Computed Tomography for the Noninvasive Assessment of Arterial Aging: A Review by the VascAgeNet COST Action
Magnetic resonance imaging and computed tomography allow the characterization of arterial state and function with high confidence and thus play a key role in the understanding of arterial aging and its translation into the clinic. Decades of research into the development of innovative imaging sequences and image analysis techniques have led to the identification of a large number of potential biomarkers, some bringing improvement in basic science, others in clinical practice. Nonetheless, the complexity of some of these biomarkers and the image analysis techniques required for their computation hamper their widespread use. In this narrative review, current biomarkers related to aging of the aorta, their founding principles, the sequence, and postprocessing required, and their predictive values for cardiovascular events are summarized. For each biomarker a summary of reference values and reproducibility studies and limitations is provided. The present review, developed in the COST Action VascAgeNet, aims to guide clinicians and technical researchers in the critical understanding of the possibilities offered by these advanced imaging modalities for studying the state and function of the aorta, and their possible clinically relevant relationships with aging.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e027414
Magnetic Resonance Imaging and Computed Tomography for the Noninvasive Assessment of Arterial Aging: A Review by the VascAgeNet COST Action
Magnetic resonance imaging and computed tomography allow the characterization of arterial state and function with high confidence and thus play a key role in the understanding of arterial aging and its translation into the clinic. Decades of research into the development of innovative imaging sequences and image analysis techniques have led to the identification of a large number of potential biomarkers, some bringing improvement in basic science, others in clinical practice. Nonetheless, the complexity of some of these biomarkers and the image analysis techniques required for their computation hamper their widespread use. In this narrative review, current biomarkers related to aging of the aorta, their founding principles, the sequence, and postprocessing required, and their predictive values for cardiovascular events are summarized. For each biomarker a summary of reference values and reproducibility studies and limitations is provided. The present review, developed in the COST Action VascAgeNet, aims to guide clinicians and technical researchers in the critical understanding of the possibilities offered by these advanced imaging modalities for studying the state and function of the aorta, and their possible clinically relevant relationships with aging.
- Open Access
- 6 May 2023
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 42 (10) , 2183-2213
The Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action
Non‐invasive ultrasound (US) imaging enables the assessment of the properties of superficial blood vessels. Various modes can be used for vascular characteristics analysis, ranging from radiofrequency (RF) data, Doppler‐ and standard B/M‐mode imaging, to more recent ultra‐high frequency and ultrafast techniques. The aim of the present work was to provide an overview of the current state‐of‐the‐art non‐invasive US technologies and corresponding vascular ageing characteristics from a technological perspective. Following an introduction about the basic concepts of the US technique, the characteristics considered in this review are clustered into: 1) vessel wall structure; 2) dynamic elastic properties, and 3) reactive vessel properties. The overview shows that ultrasound is a versatile, non‐invasive, and safe imaging technique that can be adopted for obtaining information about function, structure, and reactivity in superficial arteries. The most suitable setting for a specific application must be selected according to spatial and temporal resolution requirements. The usefulness of standardization in the validation process and performance metric adoption emerges. Computer‐based techniques should always be preferred to manual measures, as long as the algorithms and learning procedures are transparent and well described, and the performance leads to better results. Identification of a minimal clinically important difference is a crucial point for drawing conclusions regarding robustness of the techniques and for the translation into practice of any biomarker.
- 6 May 2023
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 42 (10) , 2183-2213
Open AccessThe Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action
Non‐invasive ultrasound (US) imaging enables the assessment of the properties of superficial blood vessels. Various modes can be used for vascular characteristics analysis, ranging from radiofrequency (RF) data, Doppler‐ and standard B/M‐mode imaging, to more recent ultra‐high frequency and ultrafast techniques. The aim of the present work was to provide an overview of the current state‐of‐the‐art non‐invasive US technologies and corresponding vascular ageing characteristics from a technological perspective. Following an introduction about the basic concepts of the US technique, the characteristics considered in this review are clustered into: 1) vessel wall structure; 2) dynamic elastic properties, and 3) reactive vessel properties. The overview shows that ultrasound is a versatile, non‐invasive, and safe imaging technique that can be adopted for obtaining information about function, structure, and reactivity in superficial arteries. The most suitable setting for a specific application must be selected according to spatial and temporal resolution requirements. The usefulness of standardization in the validation process and performance metric adoption emerges. Computer‐based techniques should always be preferred to manual measures, as long as the algorithms and learning procedures are transparent and well described, and the performance leads to better results. Identification of a minimal clinically important difference is a crucial point for drawing conclusions regarding robustness of the techniques and for the translation into practice of any biomarker.
- Open Access
- 31 March 2022
- Published by Springer Nature in Artery Research
- Vol. 28 (2) , 55-60
Medical Device Regulation: Should We Care About It?
Medical devices are subject to strict regulatory and approval processes to enter the market and to be used by operators and patients. These are needed to guarantee the users’ safety. The different activities of these processes have important implications for all involved stakeholders and for the whole lifecycle of a medical device. The aim of this work is to provide an overview of some key aspects of the new EU Medical Device Regulation and to show why researchers, innovators and clinicians should care about it. Awareness of regulatory requirements can improve the innovation process and its efficiency in terms of both social and ethical impact, but this awareness needs to be raised in the upcoming months and years. One can shortly say “yes, one needs to take care” of the new EU Medical Device Regulation. First and foremost, it is crucial for the sake of the users’ safety, which is the regulation’s intrinsic goal. Second, it should not just be seen as an obstacle for new innovations in the medical domain, but as a chance as it can provide new opportunities.
- 31 March 2022
- Published by Springer Nature in Artery Research
- Vol. 28 (2) , 55-60
Open AccessMedical Device Regulation: Should We Care About It?
Medical devices are subject to strict regulatory and approval processes to enter the market and to be used by operators and patients. These are needed to guarantee the users’ safety. The different activities of these processes have important implications for all involved stakeholders and for the whole lifecycle of a medical device. The aim of this work is to provide an overview of some key aspects of the new EU Medical Device Regulation and to show why researchers, innovators and clinicians should care about it. Awareness of regulatory requirements can improve the innovation process and its efficiency in terms of both social and ethical impact, but this awareness needs to be raised in the upcoming months and years. One can shortly say “yes, one needs to take care” of the new EU Medical Device Regulation. First and foremost, it is crucial for the sake of the users’ safety, which is the regulation’s intrinsic goal. Second, it should not just be seen as an obstacle for new innovations in the medical domain, but as a chance as it can provide new opportunities.